Written and maintained by CASRAI Editorial Board
Last updated
Short answer: both techniques exist to solve the same problem — a treatment allocation sequence generated by pure chance can, especially in a small or moderate trial, still produce groups that are badly imbalanced on an important prognostic factor (age band, disease stage, study site). Stratified randomisation solves it by running a separate randomisation list — usually a permuted block — inside each combination of strata, so balance within every stratum is baked into the mechanism itself. Minimisation solves it differently: it is a dynamic, run-time algorithm that looks at every factor’s current imbalance each time a new participant is enrolled and assigns them (deterministically, or with a heavily weighted “biased coin”) to whichever arm would minimise the overall imbalance. They are not the same procedure with two names, and picking between them is a real design decision, not a formatting preference — the choice changes what a Data Monitoring Committee can unblind, what your statistician has to pre-specify, and how well the design scales as you add balancing factors.
Why plain randomisation isn’t enough
Simple randomisation (a coin flip, or its computerised equivalent) guarantees that allocation is unpredictable and free of selection bias, which is the property random assignment exists to buy in the first place. What it does not guarantee, particularly at the sample sizes most trials actually run at, is that the arms end up balanced on baseline characteristics that are known to affect the outcome. A trial of 80 participants split by simple randomisation can, entirely by chance, land 60/40 on a binary prognostic factor like disease severity — and once that happens, the treatment effect estimate is confounded with the imbalance, forcing the analysis to lean on covariate adjustment to recover what the design should have prevented. Stratified randomisation and minimisation are the two standard ways trialists prevent that from happening at the design stage rather than the analysis stage.
Stratified randomisation: blocks within strata
Stratified randomisation defines strata — every combination of levels of the factors you want balanced (e.g., site × disease stage, or age band × sex) — and runs an independent permuted-block randomisation list within each one. Inside a single stratum, participants are assigned in blocks (commonly of size 4 or 6) so that, at the end of every complete block, the arms are exactly or near-exactly balanced within that stratum. This is the same block-randomisation mechanism used in an unstratified trial; stratification just means you’re running many small, parallel copies of it, one per stratum, instead of one large one.
The practical constraint is combinatorial. Every stratification factor multiplies the number of strata by its number of levels: two binary factors (site type × sex) give four strata; add a three-level disease-stage factor and you have twelve; add a fourth two-level factor and you’re at twenty-four. Each stratum needs enough participants for its blocks to actually fill and balance — a stratum that enrols only two or three participants before the trial closes may never complete a block, which defeats the purpose and can even make within-stratum imbalance worse than plain randomisation would have. This is the standard, well-established caution in trial methodology texts: keep the number of strata small relative to the expected sample size, and in practice that usually means no more than two or three stratification factors in a moderately sized trial — a multi-centre trial with many sites already “spends” one stratification factor on site alone, which is why site-stratified randomisation with one or two additional clinical factors is a common ceiling, not an arbitrary one.
The other design decision stratified randomisation forces is block size disclosure. A fixed, guessable block size lets site staff anticipate the next allocation once they’ve seen a run of assignments (accidental unblinding), which is why many protocols use randomly varying block sizes within each stratum rather than a single fixed size throughout.
Minimisation: balancing many factors dynamically
Minimisation, introduced by Taves and independently by Pocock and Simon in the mid-1970s, takes a different approach: there is no pre-generated allocation list at all. Instead, each time a new participant is enrolled, the algorithm looks at every arm’s current totals across every balancing factor, calculates a measure of the imbalance that would result from assigning this participant to each available arm, and assigns them to whichever arm minimises that overall imbalance. In its deterministic form, the arm that minimises imbalance simply wins every time; in its more common biased-coin form, that arm is given a high but not absolute probability (commonly around 0.7–0.8) of being chosen, with the complementary probability going to the other arm(s) — preserving an element of unpredictability that pure determinism lacks.
The advantage minimisation has over stratified block randomisation is scaling: because it balances marginal totals for each factor rather than requiring a filled cell for every combination of factors, it does not suffer the combinatorial explosion described above. A trial balancing on five or six prognostic factors is impractical to stratify (the strata would vastly outnumber the participants) but entirely workable with minimisation, since the algorithm only ever needs each individual factor’s running totals to stay balanced, not a fully populated joint table of every factor combination.
The trade-off is procedural, not statistical. Minimisation is dynamic and history-dependent — the eleventh participant’s allocation probability depends on exactly how the first ten were assigned and on which factors that specific participant carries — which means it cannot be reduced to a single pre-generated randomisation list the way blocked randomisation can. That has two real consequences a protocol has to address explicitly:
- The algorithm itself must be fully documented and fixed before the trial starts — the exact factors used, their relative weights if unequal, the imbalance metric (e.g., range or variance of arm totals across factors), the biased-coin probability if one is used, and how ties are broken. Because the next allocation can, in principle, be inferred by anyone who knows the algorithm and has seen the running totals, that documentation has to live in the protocol or a separate randomisation charter that is itself access-controlled, not left implicit.
- Implementation is usually software-mediated — an IRT/RTSM system computing the running imbalance and next allocation in real time — rather than a list a pharmacist or coordinator can hold in advance, which has operational implications for how allocation concealment and any interim unblinding request are handled.
Stratified randomisation vs. minimisation, side by side
| Stratified randomisation | Minimisation | |
|---|---|---|
| Mechanism | Independent permuted-block list within every stratum (every factor combination) | Dynamic algorithm evaluates imbalance and assigns at the moment of enrolment |
| Scales with factors how | Poorly — strata multiply combinatorially with each added factor and level | Well — balances marginal totals per factor, no combinatorial blow-up |
| Typical ceiling | Two to three factors in a moderately sized trial before strata become too sparse | Five or more factors is routine |
| Pre-specification needs | Block size(s) and whether they vary randomly, stratum definitions | Full algorithm: factors, weights, imbalance metric, biased-coin probability, tie-break rule — usually its own charter |
| Allocation predictability risk | Fixed block size is guessable near the end of a block (“accidental unblinding”) | Deterministic form is more predictable than biased-coin form; both depend on visible running totals |
| Typical implementation | Pre-generated list, can be prepared by a statistician in advance and released to an IRT/RTSM system or sealed envelopes | Requires real-time computation, almost always software (IRT/RTSM), not a pre-generated list |
| Analysis implication | Analysis should adjust for the stratification factors used in randomisation | Analysis should adjust for the factors used in minimisation, same underlying principle |
The shared analysis requirement
Both techniques carry the same downstream obligation, and it is one that gets missed more often than the randomisation design itself: when a factor was used to balance allocation, the primary analysis should account for it. Regulatory statistical guidance on trial design is explicit that when randomisation is stratified (or balanced via minimisation), the analysis should reflect the design used to generate the treatment assignments — typically by including the stratification/minimisation factors as covariates in the primary model, rather than analysing the trial as if allocation had been unstratified simple randomisation. Skipping this step doesn’t just leave statistical power on the table; for a stratified design it can also produce a variance estimate that no longer matches how the data were actually generated. This is one of the reasons the statistical analysis plan needs to name the exact balancing factors and confirm they will be carried into the primary model, not left to be decided after unblinding.
Which to choose
The decision usually comes down to how many factors genuinely need balancing and how the trial is run operationally:
- Choose stratified block randomisation when you have one, two, or at most three factors to balance, want a randomisation scheme that can be fully pre-generated and handed to an independent party before the trial opens, and value the conceptual simplicity of “a separate list per stratum” for audit and reporting purposes.
- Choose minimisation when you need to balance four or more prognostic factors simultaneously (common in oncology and other trials with several strong, independently-acting prognostic variables), when strata would otherwise be too sparse to fill reliably given your expected sample size, or when the trial already runs through an IRT/RTSM platform capable of computing allocations in real time.
- Some trials combine the two — for example, stratifying by site (an operational necessity, since site-level drug supply is usually organised that way regardless) while using minimisation across the remaining clinical factors within each site.
Whichever is chosen, the protocol (and, per SPIRIT item 16a) needs to name the exact method, the factors, and — for minimisation specifically — enough of the algorithm’s mechanics that a statistician reviewing the trial afterward could reconstruct how any given allocation was determined. A DMC charter reviewing accumulating data from a minimisation-randomised trial also needs to know the running imbalance statistics are themselves a possible route to inferring upcoming allocations, and should restrict who has visibility into them accordingly.
Frequently asked questions
Is minimisation a form of randomisation?
Only partially, and this is a genuine point of methodological debate. The deterministic form of minimisation contains no random element at all for the participant whose allocation minimises current imbalance — their arm is simply chosen. The biased-coin form restores an explicit random element (typically assigning the imbalance-minimising arm with probability 0.7–0.8 rather than 1.0), which is why most current guidance favours the biased-coin variant over the strictly deterministic one when using minimisation in a regulated trial.
Does minimisation replace the need for blinding?
No — allocation method and blinding are independent design choices. A minimisation-randomised trial can be double-blind, single-blind, or open-label exactly as any other design can; minimisation only concerns how the next arm is chosen, not whether participants or investigators know which arm was chosen.
Can stratified randomisation and minimisation both be used in the same trial?
Yes — stratifying by one operationally necessary factor (site is the most common) while using minimisation across additional clinical factors within each site is an established combined approach, used specifically to avoid the sparse-stratum problem that would result from stratifying by all factors at once.
How is stratified randomisation different from stratified sampling?
They solve different problems at different stages of a study. Stratified sampling concerns how participants are selected into a study from a wider population, in proportion to strata in that population, to support generalisability. Stratified randomisation concerns how participants already enrolled in a trial are allocated to treatment arms, to support balance and internal validity. A study can use one, both, or neither.
Related reading: Random Assignment vs Random Sampling, Cluster Randomised Trials and the Intracluster Correlation Coefficient, What Is a Control Group?, and Intention-to-Treat Analysis.
